Metabolic collaborates with Roche to establish early Alzheimer’s screening research initiative in Dubai

UAE—Metabolic (formerly GluCare.Health) has entered a strategic partnership with Roche to introduce Elecsys® pTau217 plasma immunoassay testing as part of a research-focused screening program for early Alzheimer’s disease detection.

The initiative targets individuals with elevated metabolic risk, including patients with diabetes, obesity, hypertension, and dyslipidemia, and will be conducted at Metabolic facilities in Dubai.

Unlike conventional approaches that focus on symptomatic patients, the program evaluates asymptomatic individuals who already carry metabolic risk factors linked to cognitive decline.

The Elecsys® pTau217 blood-based biomarker, developed by Roche, has demonstrated diagnostic performance comparable to cerebrospinal fluid testing and PET imaging, with reported accuracy ranging from AUC 0.93 to 0.96.

Study design and clinical focus

The collaboration will operate as a 12–24-month prospective, non-interventional cohort study in partnership with Roche Diagnostics Middle East.

It will enroll 500 participants and compare plasma p-Tau217 results with clinical assessments and established CSF biomarkers.

Researchers aim to assess the reliability of p-Tau217 in identifying early Alzheimer’s pathology and evaluate its potential as a scalable tool for long-term monitoring.

The study also builds on growing clinical interest in the link between metabolic dysfunction and neurodegeneration, often discussed in relation to “Type 3 diabetes,” a term used to describe cognitive decline linked to insulin resistance and chronic inflammation.

Integrated hybrid care model

Participants who test positive for elevated risk markers will be enrolled in Metabolic’s Hybrid Care Program.

The model combines structured lifestyle intervention with clinical and digital health support, including dietitians, fitness trainers, and health coaches working alongside patients.

In addition, wearable devices will continuously track sleep, stress, glucose levels, and physical activity, enabling real-time data integration into patient care plans.

The program also explores emerging evidence suggesting that p-Tau217 levels may respond dynamically to lifestyle changes, such as exercise, and to pharmacological interventions approved for the treatment of Alzheimer’s disease.

Roche Diagnostics perspective and broader collaboration

Roche emphasized its expanding neuroscience portfolio, which includes blood-based biomarkers such as pTau217, pTau181, and ApoE4 assays, alongside cerebrospinal fluid and digital diagnostic tools.

The company continues to expand collaborations with clinicians and health systems to advance early detection and improve disease monitoring across care pathways.

Recent industry discussions have also reflected increasing global momentum toward blood-based Alzheimer’s diagnostics, particularly in preventive and high-risk population screening models, aligning with initiatives such as this partnership in the Middle East.

Advancing preventive neurology in metabolic care

Through this collaboration, Metabolic is positioning metabolic clinics as early detection hubs for neurodegenerative risk, integrating Alzheimer’s screening into chronic disease management frameworks.

The initiative expands the use of Elecsys® pTau217 beyond diagnostic settings into preventive, population-level research focused on early intervention strategies for at-risk groups.